Biosensors are established as promising analytical tools for detecting various analytes important in biomedicine and environmental monitoring. Using fiber optic technology as a sensing element in biosensors offers low cost, high sensitivity, chemical inertness, and immunity to electromagnetic interference. Optical fiber sensors can be used in in vivo applications and multiplexed to detect several targets simultaneously. Certain configurations of optical fiber technology allow the detection of analytes in a label-free manner. This review aims to discuss recent advances in label-free optical fiber biosensors from a technological and application standpoint. First, modern technologies used to build label-free optical fiber-based sensors will be discussed. Then, current applications where these technologies are applied are elucidated. Namely, examples of detecting soluble cancer biomarkers, hormones, viruses, bacteria, and cells are presented.

The osteochondral interface (OCI) is a structurally and functionally complex tissue whose degeneration or injury often results in poor healing and joint dysfunction due to its avascular and hypocellular nature. Conventional surgical treatments remain suboptimal, prompting growing interest in regenerative approaches, particularly with the utilization of hydrogel-based biomaterials that can mimic the extracellular matrix and support osteochondral regeneration. This study reviewed types of hydrogels, scaffold processing techniques, and animal models for OCI regeneration. Our search demonstrated that gelatin, alginate, chitosan, and hyaluronic acid were the most frequently investigated hydrogels. Layered constructs dominated current scaffold designs, while advanced methods such as 3D printing and extrusion demonstrated unique potential to create graded architectures resembling the native OCI. Rabbits were the most widely used in vivo models, though translation will require larger animal studies with clinically relevant defect sizes. Future efforts should focus on developing mechanically reinforced, biologically active, and continuously graded hydrogels, supported by standardized preclinical validation in large-animal models, to accelerate translation toward clinical solutions for osteochondral regeneration.

A semi-distributed interferometer is a low-reflectivity device with refractive index sensing capability, exploiting the random reflectivity of a nanoparticle-doped fiber to form a weak distributed cavity. In this work, we extend this concept to an extrinsic semi-distributed interferometer (ESDI), using an overlay made of polydimethylsiloxane (PDMS) around the fiber tip; this structure can then be surface-modified using a thin metallic film or a nanoparticle coating. We report gold-sputtered and gold-nanoparticle-coated ESDI structures for refractive index sensing capability, with the latter achieving superior performances with an average sensitivity of 62.8 dB/RIU (refractive index units) with resolution of 3.9 × 10⁻⁵ RIU over the range of 1.34790–1.35981. We also report a possible biological application using a biofunctionalized version of this probe for the detection of VEGF (vascular endothelial growth factor); the gold-sputtered probe achieves the highest sensitivity, 0.0565 dB for each 10× concentration increase, with 355 fM detection limit.

Osteoarthritis (OA) and osteochondral degeneration present a significant clinical burden characterized by the complex interplay of extracellular matrix degradation and chronic inflammation. While biochemical profiling has matured, a critical translational gap remains in transitioning from benchtop assays to systems capable of continuous, intra-articular monitoring. This review provides a comprehensive synthesis of experimentally validated biosensing technologies, including optical, electrochemical, and piezoelectric Quartz Crystal Microbalance (QCM) platforms, evaluated through the lens of sensing architecture, biomarker specificity, and matrix compatibility. Our analysis reveals that while optical sensors offer superior sensitivity, electrochemical platforms show the greatest promise for miniaturized, implantable integration. However, a pivot in the field is identified: the primary bottleneck has shifted from analytical detection limits to operational stability within the hostile synovial environment. Current research is largely restricted to single-analyte detection in simplified media, failing to address the multifactorial nature of OA. We propose that the next generation of osteochondral diagnostics must prioritize multiplexed arrays, mechanically compliant architectures, and machine-learning-assisted signal processing. By bridging these engineering frontiers, biosensors will evolve from passive diagnostic tools into intelligent, personalized platforms for real-time disease management.